Merck To Pay $688M To Settle Investor Suits Over Vytorin
Merck & Co. said Thursday it will pay $688 million to settle two class actions alleging the drugmaker and subsidiary Schering-Plough hid test results for their anti-cholesterol drug Vytorin from investors,...To view the full article, register now.
Already a subscriber? Click here to view full article